Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

Area of Science:

• Cancer Biology
• Immunology
• Molecular Signaling

Background:

• Programmed death-ligand 1 (PD-L1) is upregulated in many cancers, aiding immune evasion.
• The roles of tumor microenvironment versus cancer cell-intrinsic signaling in PD-L1 regulation are not fully understood.

Purpose of the Study:

• To investigate the mechanism by which oncogenic RAS signaling regulates PD-L1 expression within cancer cells.
• To explore the therapeutic potential of targeting this pathway in RAS-mutant cancers.

Main Methods:

• Analysis of PD-L1 mRNA stability and regulation by tristetraprolin (TTP).
• Investigating the role of MEK/MK2 signaling in TTP inhibition downstream of RAS.
• Correlating RAS pathway activation with PD-L1 expression in human lung and colorectal tumors.
• Assessing the impact of TTP restoration on anti-tumor immunity in vivo.

Main Results:

• Oncogenic RAS signaling increases PD-L1 mRNA stability by inhibiting TTP, a negative regulator of PD-L1.
• MEK signaling phosphorylates and inhibits TTP via MK2.
• RAS pathway activation correlates with elevated PD-L1 in human lung and colorectal tumors.
• Restoring TTP enhances anti-tumor immunity through PD-L1 mRNA degradation.

Conclusions:

• RAS signaling drives cell-intrinsic PD-L1 expression, contributing to immune resistance.
• Targeting the RAS-TTP axis offers therapeutic opportunities for RAS-mutant cancers.
• Modulating TTP can reverse the immunosuppressive phenotype of these tumors.